Pretreatment HIV drug resistance predicts accumulation of new mutations in ART‐naïve Ugandan children
| Autor: | Johanna Rubin, Sarah Nanzigu, Celestino Obua, Sandra Soeria-Atmadja, Pauline Amuge, Lars L. Gustafsson, Lars Navér, Jaran Eriksen, Adeodata Kekitiinwa, Dickson Bbuye |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Efavirenz Genotype Anti-HIV Agents HIV Infections Viremia Drug resistance Virus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine 030225 pediatrics Internal medicine Drug Resistance Viral Humans Medicine Uganda 030212 general & internal medicine Child business.industry virus diseases General Medicine medicine.disease Reverse transcriptase chemistry Mutation Pediatrics Perinatology and Child Health Cohort HIV-1 business Viral load HIV drug resistance |
| Zdroj: | Acta Paediatrica. 109:2706-2716 |
| ISSN: | 1651-2227 0803-5253 |
| DOI: | 10.1111/apa.15320 |
| Popis: | AIM To assess the prevalence of pretreatment drug resistance (PDR) and its association with virologic outcomes after 24 weeks of antiretroviral therapy (ART), within an urban cohort of Ugandan children. METHODS Prospective observational study. Baseline and 24-week assessments of viral load (VL) and genotypic drug resistance to nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) were performed. RESULTS Ninety-nine ART-naive children (3-12 years) initiated efavirenz-based ART 2015-2016 and 18/90 (20%) had baseline NRTI/NNRTI associated drug resistance mutations (DRMs). By 24 weeks, 72/93 (77%) children had VL |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text